Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole;Rhabdomyolyse unter der kombination atorvastatin, amiodaron und fluconazol

Praxis

Volumn 100, Issue 5, 2011, Pages 273-284

  Franz, Carmen ^a   Bruggisser, M ^a   Krahenbuhl S ^a   Ratz Bravo A E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Amiodarone; Fluconazole; Myopathy; Rhabdomyolysis; Statin

Indexed keywords

AMIODARONE; ATORVASTATIN; FLUCONAZOLE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; CRITICAL ILLNESS MYOPATHY; DRUG WITHDRAWAL; GOUT; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; INFECTION; MALE; MYOPATHY; RHABDOMYOLYSIS; SIDE EFFECT; STERNAL INFECTION;

EID: 79952326957     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a000491     Document Type: Article

References (55)

1. Sathasivam S, Lecky B. Statin inducedmyopathy. BMJ 2008;337:a2286.
2. Micromedex® 1.0 (Healthcare Series), (electronic version). Thomson Reuters (Healthcare) Inc., Greenwood Village, Colorado, USA. Available at: http://www.thomsonhc.com(cited 01/04/2011).
3. American Psychiatric Association. Medication-induced movement disorders: neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington D.C.: American Psychiatric Association 2000: 795-798.
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
5. Arzneimittelkompendiumder Schweiz (online). Basel: Documed AG, updated periodically. (Accessed January 2011 at www.kompendium.ch)
6. Finsterer J. [Diagnosis ofmyopathies]. Fortschr Neurol Psychiatr 2010;78:382-393.
7. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002;106:1024-1028. (Pubitemid 34925341)
8. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009;80:832-838.
9. Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009;22:506-515.
10. Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 2008;19:568-574.
11. Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009;67:272-283.
12. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-1107. (Pubitemid 32880030)
13. Hamer R. When exercise goes awry: exertional rhabdomyolysis. South Med J 1997;90:548-551. (Pubitemid 27376958)
14. Poels PJ, Gabreels FJ. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993;95:175-192. (Pubitemid 23288234)
15. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006;97:6C-26C.
16. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010;12:322-330.
17. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414. (Pubitemid 43228152)
18. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-25890.
19. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-540.
20. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-2676. (Pubitemid 41785067)
21. Mammen AL, Amato AA. Statinmyopathy: a review of recent progress. Curr Opin Rheumatol 2010;22:644-650.
22. Teichmann LL, Fleck M. [Current views on lipid metabolism: statin-induced myopathy]. Z Rheumatol 2010;69:696-8, 700-701.
23. Mas E, Mori TA. Coenzyme Q(10) and Statin Myalgia: What is the Evidence? Curr Atheroscler Rep 2010;12:407-413.
24. Aronson JK e. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. 15th ed. (Online version): Elsevier; 2006: 1632ff.
25. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-66.
26. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-317. (Pubitemid 24167378)
27. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-854.
28. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008;8:333-338.
29. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 2009;4:209-228.
30. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690. (Pubitemid 37430274)
31. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005;329:1067-1075. (Pubitemid 40341384)
32. Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009;181:E11-8.
33. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316. (Pubitemid 39223221)
34. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. (Pubitemid 40471450)
35. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559. (Pubitemid 44202151)
36. Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 2009;43:2012-2020.
37. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33:171-187.
38. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-799.
39. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-37168.
40. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11-28 [abstract].
41. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-581. (Pubitemid 44908269)
42. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-320. (Pubitemid 47041993)
43. Doser M, Eberle B. [Preoperative preparation of patients with cardiovascular disease for noncardiac surgery]. Ther Umsch 2009;66:525-530.
44. Buse GL, Bucher E, Seeberger MD, Filipovic M. [Perioperative management of chronic medication: to withhold, continue or intensify?]. Ther Umsch 2009;66:509-517.
45. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49: 2231-2237. (Pubitemid 46856819)
46. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithmfor diagnosis andmanagement ofmyalgia. Mayo Clin Proc 2008;83:687-700. (Pubitemid 351810569)
47. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101:490-496. (Pubitemid 351199443)
48. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-868.
49. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-346. (Pubitemid 351429598)
50. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-485. (Pubitemid 351199439)
51. Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc 2007;82:539-542. (Pubitemid 46709420)
52. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370. (Pubitemid 34713089)
53. Klopstock T. Drug-induced myopathies. Curr Opin Neurol 2008;21:590-595.
54. Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf 2007;2:47-63 [abstract].
55. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000;11:1553-1561. (Pubitemid 30483474)